OncoMatch/Clinical Trials/NCT04009265
Study Compare Adjuvant Chemotherapy, Chemoradiotherapy and Surgery Alone for pN1-2(pT1b-3N1-2M0) Esophageal Carcinoma
Is NCT04009265 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies adjuvant treatment for esophageal squamous cell carcinoma.
Treatment: adjuvant treatment — A multi-center prospective randomized controlled study was conducted to compare the effects of adjuvant chemotherapy, chemoradiotherapy and surgery alone for the patients with esophageal cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage PN1-2, PT1B-3N1-2M0 (AJCC 8th edition)
According to the 8th edition of AJCC staging, pN1-2 (pT1b-3N1-2M0) stage of esophageal cancer
Performance status
WHO 0–1
Prior therapy
Must have received: surgery — curative (R0 resection)
Radical resection of tumors (R0) was performed
Cannot have received: antineoplastic treatment
No antineoplastic treatments before operation
Cannot have received: anti-tumor treatment
Received other anti-tumor treatment before enrollment
Lab requirements
Kidney function
Laboratory examination within one week before the adjuvant treatment confirmed that the renal function met the requirements
Liver function
Laboratory examination within one week before the adjuvant treatment confirmed that the hepatic function met the requirements
Cardiac function
Laboratory examination within one week before the adjuvant treatment confirmed that the cardiac function met the requirements
Laboratory examination within one week before the adjuvant treatment confirmed that the cardiac, hepatic and renal functions met the requirements
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify